新技术视野:FAST-FNA实现头颈癌快速多重生物标志物分析
本文为综述,讨论头颈癌基于临床的生物标志物检测在真实世界中的挑战,并介绍基于细针穿刺(FNA)的生物标志物检测优势。作者提出FAST-FNA(快速分析筛查技术)概念,该技术正在开发中,旨在指导头颈癌免疫治疗选择并辅助下一代预测性生物标志物研发。
要点
- PD-L1检测已获FDA批准作为头颈癌抗PD1治疗的伴随诊断。
- 现有临床工作流程限制生物标志物检测的常规开展与应用。
- FAST-FNA可在FNA样本上实现快速多重生物标志物分析。
核心结论
- FAST-FNA技术正在开发中,旨在指导头颈癌免疫治疗选择并辅助下一代预测性生物标志物研发。
研究设计与样本
- 综述,讨论头颈癌基于临床的生物标志物检测挑战及FNA-based检测的优势,并介绍FAST-FNA概念与技术革新。
主要发现
- PD-L1 profiling近期获美国FDA批准作为头颈癌患者抗PD1治疗的伴随诊断。
- 当前临床工作流程和缺乏更好更全面的替代方案限制了此类检测的常规开发与实施。
- 基于FNA的生物标志物检测可实现频繁和连续的肿瘤采样。
临床怎么用
- FAST-FNA有望在头颈癌中实现快速多重生物标志物分析,辅助免疫治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PD-L1 profiling was recently approved by the US Food and Drug Administration as a companion diagnostic for anti-PD1 treatment in patients with head and neck cancer, ushering in a new era for precision medicine. However, the routine development and implementation of such testing is still limited by current clinical workflows and the lack of better and more comprehensive alternatives. In this review, the authors discuss the real-world challenges of clinically based biomarker testing and highlight the advantages of developing fine-needle aspiration (FNA)-based biomarker testing that would enable frequent and serial tumor sampling. A conceptual and technological innovation is introduced, fast analytical screening technique (FAST)-FNA (FAST chemistry-enabled FNA), which is being developed to inform immunotherapy treatment options in patients with head and neck cancer and to assist with the development of the next generation of predictive biomarkers.
引用
- Pai SI, Faquin WC, Sadow PM, et al. New technology on the horizon: Fast analytical screening technique FNA (FAST-FNA) enables rapid, multiplex biomarker analysis in head and neck cancers. Cancer Cytopathol. 2020. PMID: 32841527. doi:10.1002/cncy.22305
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。